MHRA Warns Women Using GLP-1 Receptor Agonists for Weight Loss to Use Effective Contraception Due to Pregnancy Risks

The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a warning to women using GLP-1 receptor agonists (GLP-1RAs) for weight loss, emphasizing the need to use effective contraception while undergoing treatment. The advisory highlights potential risks associated with these medications during pregnancy and comes amid concerns about patients accessing such treatments through unregulated channels where critical safety information may not be adequately disclosed.

GLP-1RAs, originally developed for managing type 2 diabetes, have gained popularity as weight-loss aids. However, the MHRA cautions that these drugs could pose risks to fetal development if used during pregnancy. The agency notes that some individuals are obtaining these medications outside regulated healthcare systems, which may result in insufficient communication of safety guidelines. Women of childbearing age using GLP-1RAs are advised to ensure they use reliable contraceptive methods throughout their treatment period. This alert underscores the importance of accessing medical treatments through authorized providers who can offer comprehensive guidance on usage and associated risks.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

Date: June 5, 2025

Related posts:

Human Thought Lags Behind Sensory Speed The Trump Administration’s Impact on NIH and other Federal Health Agencies DrugPatentWatch Identifies Strategies to Enhance Generic Drug Affordability and Market Share Drug Patent Watch Guide Focuses on Data Analytics, Value-Based Pricing for Pharmaceutical Market Share.

Author

Mark Chiang